ERR2208957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- INFLAMMATORY_RESPONSE+0.500
- COMPLEMENT+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.300
- APOPTOSIS+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.500
- DNA_REPAIR-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- E2F_TARGETS-0.200
- HEDGEHOG_SIGNALING-0.200
- MTORC1_SIGNALING-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- P53_PATHWAY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.892 |
| 2 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.888 |
| 3 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.882 |
| 4 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.873 |
| 5 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.872 |
| 6 | TCGA-97-7553-01A-21R-2039-07 | — | cohortA1 | 0.872 |
| 7 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.869 |
| 8 | MDT-AP-2936 | Med | Medulloblastoma | 0.854 |
| 9 | bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b | — | — | 0.853 |
| 10 | SRR8526722 | — | cohortMD2 | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |